Q2 2021 Harmony Biosciences Holdings Inc Earnings Call

[music].

Good day and thank you for your Fannie Mae and welcome to the second quarter 2021 financial and business update conference call.

At this time all participants are in a listen only mode. After the speaker's presentation. There will be a question and answer session to ask the question doing that session you would need to press star 1 on your telephone. Please be advised that today's conference is being recorded if you required any further assistance. Please press star zero and I would now like to handicap.

<unk> the speaker, Lisa cap of R&D head of Investor Relations.

Thank you operator, good morning, everyone and thank you for joining US today as we review Harmony Biosciences second quarter 2021 financial performance and provide business update.

Before we start I encourage everyone to go to the investors section of the harmony Biosciences website to find the press release and slides that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures at the.

The state of our lifecycle, we believe non-GAAP financial results better represent the underlying economics of our business.

Our presenters on today's call are John Baker, President and CEO, Dr. Jeffrey gain of Chief Medical Officer, Jeff <unk>, Chief Commercial officer, and Sandeep Kit Paviour CFO.

Moving on to slide number 2 as a reminder, we will be making forward looking statements today, which are based on our current expectations and beliefs and these statements are subject to certain risks and uncertainties and our actual results may differ materially I and.

Encourage you to consult the risk factors referenced in our SEC filings for additional details.

At this time I would like to turn the call over to our CEO John Jacob John.

Thank you Lisa and I would also like to extend my sincere. Thanks to all of the participants for joining our second quarter 2021 conference call today.

We are halfway through the year and I am extremely pleased with the progress our team has made to date.

Please allow me to elaborate on our achievements and the context of our 3 pillars growth strategy, which is shown on slide 3.

Hello, Juan and optimize the commercial performance of Waco.

Q2 represented a strong quarter for harmony as we delivered nearly $74 million and net sales for wake ex and achieved our second profitable quarter in company history.

The significant growth nearly 24% versus the prior quarter Q1 was driven by a continued increase and the average number of patients on <unk> and and the number of healthcare professionals prescribing our product.

Both of which further underscores the significant unmet medical need and this market for a truly novel mechanism of action and differentiated product profile, which wake ex provides.

Moving on to pillar to cover 2 is expand the clinical and clinical utility of wake ex beyond narcolepsy.

And we are excited to now be evaluating <unk> and 2 additional rare disease patient populations beyond narcolepsy, both with significant unmet medical need and where there are no or limited approved therapies and.

In addition to our phase II clinical trial and patients with <unk> Willi syndrome that we initiated at the end of last year and Q2, we initiated the phase II trial and patients with <unk> dystrophy. We're also considering additional indications for <unk> and other rare neurological diseases, and we intend to broaden our lifecycle management efforts for this.

The unique product consistent with our strategy for long term growth.

And finally pillar 3 acquire new assets to expand our portfolio beyond Dweik ex <unk>.

Through the efforts of our dedicated business development team I am excited that we acquired our first additional assets beyond wake ex H B S..1 O 2 which is the potential first in class molecule with a novel mechanism of action.

102 gives us the opportunity to once again lead with the science and narcolepsy and other rare neurological disease.